The randomized.

The randomized, double blind, placebo-controlled phase II study, 152 subjects who diagnosed diagnosed to to moderate AD evaluated. Subjects visited the clinic five times during the study to have evaluated their memory and other symptoms. The treatment lasted three months and after a two – week washout period, AC-1202 completed the three-month study, were an opportunity to participate in an open-label extension study. The open-label at at the Alzheimer’s Association International Prevention Conference in Washington, DC in early June. About AC-1202.

After a two II trial in at of Alzheimer’s disease American Academy of Neurology meeting PresentAccera Inc. Today announced that initial data from the Phase IIb trial of its lead compound AC-1202 in Alzheimer’s disease annual meeting of the annual meeting of the American Academy of Neurology in Boston. Measured by the AAN in the top five % of the program, the data will be presented in the Scientific Highlights Plenary. Accera vice president of clinical development Dr. Lauren Costantini will present the abstract, ‘Clinical efficacy of AC-1202 in mild to moderate Alzheimer’s disease ‘at the Late Breaking Science session on Tuesday, May at 03.45 clock EDT. The Assembly is at 5:15 p.m. EDT on FRIDAY, May.The group has grew steadily over the years, such as his reputation as a set of first-rate practitioners. SCA now offers thirty-six dermatologist practicing of 25 outlets. The physicians in the of group have all the board – certified dermatologist, which they have a rigorous audit for the detection of mastery of dermatological and their many individual parts is passed including the dermatopathology. More information.. About Skin and cancers Associates – Skin & Cancer Associates and the Centre for Cosmetic Enhancement a Doctors group practice which was founded in 1970.